QR-Code

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Abstract Background Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Genevieve Dall, Cassandra J. Vandenberg, Ksenija Nesic, Gayanie Ratnayake, Wenying Zhu, Joseph H. A. Vissers, Justin Bedő, Jocelyn Penington, Matthew J. Wakefield, Damien Kee, Amandine Carmagnac, Ratana Lim, Kristy Shield-Artin, Briony Milesi, Amanda Lobley, Elizabeth L. Kyran, Emily O’Grady, Joshua Tram, Warren Zhou, Devindee Nugawela, Kym Pham Stewart, Reece Caldwell, Lia Papadopoulos, Ashley P. Ng, Alexander Dobrovic, Stephen B. Fox, Orla McNally, Jeremy D. Power, Tarek Meniawy, Teng Han Tan, Ian M. Collins, Oliver Klein, Stephen Barnett, Inger Olesen, Anne Hamilton, Oliver Hofmann, Sean Grimmond, Anthony T. Papenfuss, Clare L. Scott, Holly E. Barker
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2023-05-01
Schriftenreihe:Journal of Experimental & Clinical Cancer Research
Schlagworte:
Uterine leiomyosarcoma
Homologous recombination deficiency
PARP inhibitors
Rare cancers
Patient-derived xenografts
Online-Zugang:https://doi.org/10.1186/s13046-023-02687-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge